Osimertinib (Tagrisso) — 3rd-Generation TKI for EGFR-Mutated Lung Cancer
July 04, 2026
Osimertinib is a 3rd-generation tyrosine kinase inhibitor (TKI) targeting EGFR mutations, including the resistance mutation T790M. Widely used in lung cancer treatment in China.
## Mechanism and Advantage
Osimertinib (Tagrisso) is a 3rd-generation TKI targeting EGFR mutations — including ex19del, L858R and especially T790M (the resistance mutation against 1st/2nd-generation TKIs). The drug also crosses the blood-brain barrier, providing efficacy against brain metastases — a major challenge in EGFR+ lung cancer.
## Indications and Practice
Used in EGFR+ non-small cell lung cancer (NSCLC) in both early stages (adjuvant post-surgery) and advanced/metastatic disease. In China, EGFR mutation testing is a mandatory step in standard lung cancer treatment protocols.
## In China
Lung cancer is prevalent in China and EGFR mutation rates are higher than in Western populations. Hospitals like HYGEIA have extensive experience treating EGFR+ lung cancer with Osimertinib and newer-generation TKIs. International patients in China typically undergo comprehensive next-generation sequencing (NGS) for appropriate drug selection.
## Disclaimer
Information is for reference only. The physician determines the protocol after genetic testing.